Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary Collier

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
The American Journal of Dermatopathology|November 21, 2015
Zoledronic Acid-Induced Interface DermatitisFarah Succaria, Mary Collier, Meera Mahalingam
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 12, 2004
Phase I and pharmacokinetic study of prinomastat, a matrix metalloprotease inhibitorKenneth R Hande, Mary Collier, Linda Paradiso, et al.
Breast (Edinburgh, Scotland)|August 21, 2013
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancerGiuseppe Curigliano, Xavier Pivot, Javer Cortés, et al.
Investigational New Drugs|February 28, 2006
Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinomaElisabeth I Heath, Barbara A Burtness, Lawrence Kleinberg, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
The American Journal of Dermatopathology|November 21, 2015
Zoledronic Acid-Induced Interface DermatitisFarah Succaria, Mary Collier, Meera Mahalingam
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 12, 2004
Phase I and pharmacokinetic study of prinomastat, a matrix metalloprotease inhibitorKenneth R Hande, Mary Collier, Linda Paradiso, et al.
Breast (Edinburgh, Scotland)|August 21, 2013
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancerGiuseppe Curigliano, Xavier Pivot, Javer Cortés, et al.
Investigational New Drugs|February 28, 2006
Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinomaElisabeth I Heath, Barbara A Burtness, Lawrence Kleinberg, et al.
Pageof 1